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Human whole bloodNon-sterile pathogen-induced sepsis and sterile inﬂammation like in trauma or ischemia–reperfusion inju-
ry may both coincide with the life threatening systemic inﬂammatory response syndrome and multi-organ
failure. Consequently, there is an urgent need for speciﬁc biomarkers in order to distinguish sepsis from
sterile conditions. The overall aim of this study was to uncover putative sepsis biomarkers and biomarker
pathways, as well as to test the efﬁcacy of combined inhibition of innate immunity key players complement
and Toll-like receptor co-receptor CD14 as a possible therapeutic regimen for sepsis. We performed whole
blood gene expression analyses using microarray in order to proﬁle Gram-negative bacteria-induced in-
ﬂammatory responses in an ex vivo human whole blood model. The experiments were performed in the
presence or absence of inhibitors of complement proteins (C3 and CD88 (C5a receptor 1)) and CD14,
alone or in combination. In addition, we used blood from a C5-deﬁcient donor. Anti-coagulated whole
blood was challenged with heat-inactivated Escherichia coli for 2 h, total RNA was isolated and microarray
analyses were performed on the Affymetrix GeneChip Gene 1.0 ST Array platform. The initial experiments
were performed in duplicates using blood from two healthy donors. C5-deﬁciency is very rare, and only
one donor could be recruited. In order to increase statistical power, a technical replicate of the C5-
deﬁcient samples was run. Subsequently, log2-transformed intensities were processed by robust multichip
analysis and ﬁltered using a threshold of four. In total, 73 microarray chips were run and analyzed. The nor-
malized and ﬁltered raw data have been deposited in NCBI's Gene Expression Omnibus (GEO) and are acces-
sible with GEO Series accession number GSE55537. Linear models for microarray data were applied to
estimate fold changes between data sets and the respective multiple testing adjusted p-values (FDR q-
values). The interpretation of the data has been published by Lau et al. in an open access article entitled
“CD14 and Complement Crosstalk and Largely Mediate the Transcriptional Response to Escherichia coli in
Human Whole Blood as revealed by DNA Microarray” (Lau et al., 2015).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).and Hospital, Prinsensgate 164, 8092 Bodø, Norway. Tel.: +47 75578370.
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Speciﬁcations
Organism/cell line/tissue Human whole blood
(from healthy blood donors and a C5-deﬁcient patient)
Sex Male and female
Sequencer or array type Affymetrix Human Gene 1.0 ST Array
(GEO platform GPL6244)
Data format Normalized log2-transformed signal intensities
(CEL ﬁles)
Experimental factors Stimulation (120 min, 37 °C) with heat-inactivated
Escherichia coli strain LE392 versus PBS in
presence or absence of inhibitors of C3, CD14,
and C5aR1 (CD88)
Experimental features Ex vivo human whole blood model of inﬂammation
followed by whole blood RNA isolation and microarray
analysis (including cDNA synthesis). Signal values (SV)
from all chips were log-transformed (log2),
normalized using Robust Multichip Analysis,
and ﬁltered using a threshold of log2SV = 4.
Consent A written informed consent was obtained from all
blood donors before participation. The study
protocol was approved by the Regional Ethical
Committee (REC) of the Northern and
South-Eastern Norway Regional Health Authorities.
Sample source location Bodø, Norway
177C. Lau et al. / Genomics Data 5 (2015) 176–1831. Direct link to deposited data
The normalized and ﬁltered log2-transformed intensities are available
here: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55537.2. Experimental design, materials and methods
2.1. Ex vivo model of Gram-negative bacteria-induced inﬂammation in hu-
man whole blood
Venous blood from two healthy control donors (Ctrl, Ctrl2) and one
complement factor 5 (C5)-deﬁcient individual (C5D) was drawn into
sterile 5 mL cryo tube vials (Nunc, Roskilde, Denmark) (4 mL blood
per vial) containing the highly speciﬁc thrombin inhibitor lepirudin
(Reﬂudan®, Pharmion, Copenhagen, Denmark) at a ﬁnal concentration
of 50 μg/mL. Subsequently, the fresh anti-coagulated blood samples
were divided into 1.8 mL Nunc cryo tube vials containing
complement- and CD14 inhibitors or inhibitor controls at ﬁnal concen-
trations of 25 μM compstatin (Ac-I[CV(1MeW) QDWGAHRC]T) (kindly
provided by Prof. John Lambris), 10 μM CD88 (C5aR1)-speciﬁc C5a re-
ceptor antagonist (C5aR antagonist) AvF[OPdChaWR] (kindly provided
by Prof. John Lambris) and 50 μg/mL anti-human CD14 F(ab′)2 antibody
fragment (clone 18D11) (Diatec AS, Oslo, Norway). As inhibitor control,
a cocktail consisting of a control peptide (25 μM; kindly provided by
Prof. John Lambris) and a control F(ab′)2 (50 μg/mL; clone BH1) (Diatec
AS, Oslo, Norway) was used. After preincubation for 7 min at 37 °C on a
heating block, 1 × 106/mL (day 1, D1) or 5 × 106/mL (day 2, D2) heat-
inactivated Escherichia coli strain LE392 (ATCC 33572, Manassas, VA)
or phosphate buffered saline (PBS) containing calcium and magnesium
(Sigma, St. Louis, MO) were added, and incubation was proceeded for
120 min at 37 °C on a rock'n'roller. The ratio between the volumes for
inhibitor, blood and activator per sample was 1:5:1. The inﬂammatory
reaction was stopped by the addition of 10 mM EDTA (pH 8.0). Experi-
ments with C5D blood were set up twice, one set was performed with
C5D blood and the other with C5D blood reconstituted with 80 μg/mL
puriﬁed recombinant human C5 (Quidel, San Diego, CA) (C5DR) prior
to preincubation with inhibitors or PBS. Importantly, the Nunc cryo
tube vials used here are not entirely biocompatible, which results in a
weak bacteria-independent inﬂammatory response during the two-
hour incubation. As a reference for this background activation, we in-
cluded an additional unstimulated sample for both healthy blooddonors (Ctrl, Ctrl2) and C5D, which was terminated at time point zero
after preincubation (initial state, T0).
The ex vivo model of inﬂammation, project-speciﬁc modiﬁcations
and a detailed description of the blood donors have been published ear-
lier [1–3]. The blood donors were adult male (Ctrl2) and female (Ctrl
and C5D) Scandinavians, of whom two (Ctrl2 and C5D) displayed func-
tionally equivalent genetic deﬁciencies in mannose binding lectin
(MBL). MBL is involved in the lectin pathway of complement activation.
Genetic variations in theMBL2 gene are very frequent, and their clinical
manifestations are debated. In ourmodel, MBL deﬁciency had no impact
on the inﬂammatory responses tested earlier [2].
2.2. Sample preparation for microarray analysis
Immediately after termination of the whole blood model experi-
ments, 3 mL 1× nucleic acid puriﬁcation lysis buffer (Life Technologies,
Applied Biosystems™, Foster City, CA, USA; PN4305895) were added
per 2 mL sample. Total RNA isolation was performed batch-wise with
16 to 18 samples per plate following the standard procedure for ABI
PRISM™ 6100 Nucleic Acid PrepStation using Applied Biosystems
AB6100™ total RNA chemistry. Total RNA was recovered in 150 μL
nucleic acid puriﬁcation elution solution (Applied Biosystems™;
PN4305893) perwell. For further puriﬁcation, the RNAwas precipitated
overnight at−70 °C in the presence of 2.5 volumes ethanol (96%) and
10% 3 M sodium acetate, before it was washed in 70% ethanol, air-
dried and recovered in 60 μL elution solution. Subsequently, RNAquality
was approved using a 2100 Bioanalyzer (Agilent) and RNA concentra-
tion was determined using a Nanodrop system (Thermo). The average
RNA integrity number was estimated to be 8.8, and the average RNA
yield was 2.2 μg per mL venous blood.
2.3. DNA microarray analysis
The total experimental setup involved three independent main se-
ries (Ctrls, C5D, C5DR) consisting of four or two biological replicates
per series (two Ctrls × two days; one C5D × two days; one
C5DR × two days) and seven experimental conditions per replicate
(PBS, E. coli, E. coli+ inhibitors of C3 and CD14, alone or in combination,
inhibitor of C5aR1, or inhibitor controls). In addition to three initial state
controls (one for each individual: Ctrl, Ctrl2, C5D), this gave rise to a
total of 59 samples. Due to repeated microarray analysis (technical rep-
licate) of all D1 samples containing C5D or C5DR blood, a total of 73 ar-
rays were run and data sets are available (for a summarized overview
see Table 1).
For microarray analysis, 150 ng total RNA of each sample, in concen-
trations of minimum 50 ng/μL, was subjected to cDNA synthesis and
ampliﬁcation followed by in vitro transcription, clean-up and labeling
using Affymetrix® GeneChip®Whole Transcript (WT) Sense Target La-
belling Assay (Manual: P/N701880 Rev.4). cDNA was hybridized with
arrays of the GeneChip Gene 1.0 ST Array (Affymetrix) platform (Gene
Expression Omnibus platform ID: GPL6244). Staining and washing of
the arrays was performed using the GeneChip Hybridization, Wash
and Stain Kit (Affymetrix; P/N 900720) on the Fluidics Station 450
using protocol FS450_0007. For technical replicates of all day 1 samples
of C5D and C5DR the here described procedure was performed in dupli-
cates, starting with the same total RNA.
Scanned images of the arrays were processed using AGCC
(Affymetrix GeneChip Command Console) software. For further analy-
sis, the Affymetrix CEL ﬁles (containing probe intensities) were
imported into the Partek Genomics Suite software (Partek, Inc. MO,
USA). Expression data were normalized, background corrected and
summarized yielding normalized, log2-transformed signal intensities
using the Robust Multichip Analysis (RMA) algorithm implemented in
Partek Genomic Suit software. Finally, the intensities were ﬁltered
using a threshold of log2 intensity = 4.
Table 1
List of microarray data sets generated by this study.
GEO sample
ID
Sample title CEL ﬁle Protocol Scan date
GSM1338877 C5DR_anti-CD14 +
Compstatin_D1
10_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120
min, day1, replicate 1
6/5/2010
GSM1338878 C5DR_anti-CD14 +
Compstatin_D1_No2
10_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120
min, day 1, replicate 2
6/3/2010
GSM1338879 C5DR_anti-CD14 +
Compstatin_D2
10_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, combined C3 and CD14 inhibition, 120
min, day 2
5/13/2010
GSM1338859 C5D_C5aR antagonist_D1 11_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1, replicate 1 6/5/2010
GSM1338860 C5D_C5aR antagonist_D1_No2 11_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1, replicate 2 6/3/2010
GSM1338861 C5D_C5aR antagonist_D2 11_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, C5aR-inhibition, 120 min, day 2 5/13/2010
GSM1338880 C5DR_C5aR antagonist_D1 12_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1,
replicate 1
6/5/2010
GSM1338881 C5DR_C5aR antagonist_D1_No2 12_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1,
replicate 2
6/3/2010
GSM1338882 C5DR_C5aR antagonist_D2 12_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, C5aR-inhibition, 120 min, day 2 5/13/2010
GSM1338862 C5D_inhibitor ctrl_D1 13_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1, replicate 1 6/5/2010
GSM1338883 C5DR_inhibitor ctrl_D1 14_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1,
replicate 1
6/5/2010
GSM1338863 C5D_inhibitor ctrl_D1_No2 15_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1, replicate 2 6/3/2010
GSM1338864 C5D_inhibitor ctrl_D2 15_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, inhibitor controls, 120 min, day 2 5/13/2010
GSM1338884 C5DR_inhibitor ctrl_D1_No2 16_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1,
replicate 2
6/3/2010
GSM1338885 C5DR_inhibitor ctrl_D2 16_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, inhibitor controls, 120 min, day 2 5/13/2010
GSM1338816 ctrl2_PBS_D1 17_C2_D1.CEL Healthy donor 2, PBS, 120 min, day 1 5/20/2010
GSM1338817 ctrl2_PBS_D2 17_C2_D2.CEL Healthy donor 2, PBS, 120 min, day 2 5/28/2010
GSM1338818 ctrl_PBS_D1 17_C5_D1.CEL Healthy donor 1, PBS, 120 min, day 1 5/20/2010
GSM1338819 ctrl_PBS_D2 17_C5_D2.CEL Healthy donor 1, PBS, 120 min, day 2 5/28/2010
GSM1338820 ctrl2_E.coli_D1 18_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, uninhibited, 120 min, day 1 5/20/2010
GSM1338821 ctrl2_E.coli_D2 18_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, uninhibited, 120 min, day 2 5/28/2010
GSM1338822 ctrl_E.coli_D1 18_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, uninhibited, 120 min, day 1 5/20/2010
GSM1338823 ctrl_E.coli_D2 18_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, uninhibited, 120 min, day 2 5/28/2010
GSM1338824 ctrl2_Compstatin_D1 19_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1 5/20/2010
GSM1338825 ctrl2_Compstatin_D2 19_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, C3-inhibition, 120 min, day 2 5/28/2010
GSM1338826 ctrl_Compstatin_D1 19_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1 5/20/2010
GSM1338827 ctrl_Compstatin_D2 19_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, C3-inhibition, 120 min, day 2 5/28/2010
GSM1338844 C5D_PBS_D1 1_C5_D1.CEL C5 deﬁcient, PBS, 120 min, day 1, replicate 1 6/5/2010
GSM1338845 C5D_PBS_D1_No2 1_C5_D1_Nr2.CEL C5 deﬁcient, PBS, 120 min, day 1, replicate 2 6/3/2010
GSM1338846 C5D_PBS_D2 1_C5_D2.CEL C5 deﬁcient, PBS, 120 min, day 2 5/13/2010
GSM1338828 ctrl2_anti-CD14_D1 20_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1 5/20/2010
GSM1338829 ctrl2_anti-CD14_D2 20_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, CD14-inhibition, 120 min, day 2 5/28/2010
GSM1338830 ctrl_anti-CD14_D1 20_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1 5/20/2010
GSM1338831 ctrl_anti-CD14_D2 20_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, CD14-inhibition, 120 min, day 2 5/28/2010
GSM1338832 ctrl2_anti-CD14 +
Compstatin_D1
21_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 1 5/20/2010
GSM1338833 ctrl2_anti-CD14 +
Compstatin_D2
21_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 2 5/28/2010
GSM1338834 ctrl_anti-CD14 +
Compstatin_D1
21_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 1 5/20/2010
GSM1338835 ctrl_anti-CD14 +
Compstatin_D2
21_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 2 5/28/2010
GSM1338836 ctrl2_C5aR antagonist_D1 22_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1 5/20/2010
GSM1338837 ctrl2_C5aR antagonist_D2 22_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, C5aR-inhibition, 120 min, day 2 5/28/2010
GSM1338838 ctrl_C5aR antagonist_D1 22_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, C5aR-inhibition, 120 min, day 1 5/20/2010
GSM1338839 ctrl_C5aR antagonist_D2 22_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, C5aR-inhibition, 120 min, day 2 5/28/2010
GSM1338840 ctrl2_inhibitor ctrl_D1 24_C2_D1.CEL Healthy donor 2, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1 5/20/2010
GSM1338841 ctrl2_inhibitor ctrl_D2 24_C2_D2.CEL Healthy donor 2, 5 × E06/mL E. coli, inhibitor controls, 120 min, day 2 5/28/2010
GSM1338842 ctrl_inhibitor ctrl_D1 24_C5_D1.CEL Healthy donor 1, 1 × E06/mL E. coli, inhibitor controls, 120 min, day 1 5/20/2010
GSM1338843 ctrl_inhibitor ctrl_D2 24_C5_D2.CEL Healthy donor 1, 5 × E06/mL E. coli, inhibitor controls, 120 min, day 2 5/28/2010
GSM1338865 C5DR_PBS_D1 2_C5_D1.CEL C5 deﬁcient, C5-reconstituted, PBS, 120 min, day 1, replicate 1 6/5/2010
GSM1338866 C5DR_PBS_D1_No2 2_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, PBS, 120 min, day 1, replicate 2 6/3/2010
GSM1338867 C5DR_PBS_D2 2_C5_D2.CEL C5 deﬁcient, C5-reconstituted, PBS, 120 min, day 2 5/13/2010
GSM1338847 C5D_E.coli_D1 3_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, uninhibited, 120 min, day 1, replicate 1 6/5/2010
GSM1338848 C5D_E.coli_D1_No2 3_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, uninhibited, 120 min, day 1, replicate 2 6/3/2010
GSM1338849 C5D_E.coli_D2 3_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, uninhibited, 120 min, day 2 5/13/2010
GSM1338868 C5DR_E.coli_D1 4_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, uninhibited, 120 min, day 1, replicate 1 6/5/2010
GSM1338869 C5DR_E.coli_D1_No2 4_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, uninhibited, 120 min, day 1, replicate 2 6/3/2010
GSM1338870 C5DR_E.coli_D2 4_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, uninhibited, 120 min, day 2 5/13/2010
GSM1338850 C5D_Compstatin_D1 5_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1, replicate 1 6/5/2010
GSM1338851 C5D_Compstatin_D1_No2 5_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1, replicate 2 6/3/2010
GSM1338852 C5D_Compstatin_D2 5_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, C3-inhibition, 120 min, day 2 5/13/2010
GSM1338871 C5DR_Compstatin_D1 6_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1, replicate 1 6/3/2010
GSM1338872 C5DR_Compstatin_D1_No2 6_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, C3-inhibition, 120 min, day 1, replicate 2 6/3/2010
GSM1338873 C5DR_Compstatin_D2 6_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, C3-inhibition, 120 min, day 2 5/13/2010
GSM1338853 C5D_anti-CD14_D1 7_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1, replicate 1 6/5/2010
178 C. Lau et al. / Genomics Data 5 (2015) 176–183
Table 1 (continued)
GEO sample
ID
Sample title CEL ﬁle Protocol Scan date
GSM1338854 C5D_anti-CD14_D1_No2 7_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1, replicate 2 6/3/2010
GSM1338855 C5D_anti-CD14_D2 7_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, CD14-inhibition, 120 min, day 2 5/13/2010
GSM1338874 C5DR_anti-CD14_D1 8_C5_D1.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1,
replicate 1
6/5/2010
GSM1338875 C5DR_anti-CD14_D1_No2 8_C5_D1_Nr2.CEL C5 deﬁcient, C5-reconstituted, 1 × E06/mL E. coli, CD14-inhibition, 120 min, day 1,
replicate 2
6/3/2010
GSM1338876 C5DR_anti-CD14_D2 8_C5_D2.CEL C5 deﬁcient, C5-reconstituted, 5 × E06/mL E. coli, CD14-inhibition, 120 min, day 2 5/13/2010
GSM1338856 C5D_anti-CD14 +
Compstatin_D1
9_C5_D1.CEL C5 deﬁcient, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 1,
replicate 1
6/5/2010
GSM1338857 C5D_anti-CD14 +
Compstatin_D1_No2
9_C5_D1_Nr2.CEL C5 deﬁcient, 1 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 1,
replicate 2
6/3/2010
GSM1338858 C5D_anti-CD14 +
Compstatin_D2
9_C5_D2.CEL C5 deﬁcient, 5 × E06/mL E. coli, combined C3 and CD14 inhibition, 120 min, day 2 5/13/2010
GSM1338886 ctrl2_T0_D2 K2_T0_Dag2.CEL Healthy donor 2, PBS, 0 min, day 2 5/28/2010
GSM1338887 ctrl_T0_D2 K5_T0_Dag2.CEL Healthy donor 1, PBS, 0 min, day 2 5/28/2010
GSM1338888 C5D_T0_D2 T0_Dag1_C5_D2.CEL C5 deﬁcient, PBS, 0 min, day 2 5/13/2010
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(n = 19,695) have been used for downstream statistical analyses and
deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible
with GEO Series accession number GSE55537 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE55537).2.4. Microarray quality control analyses
RMA normalized, unﬁltered log2 intensities of all individual arrays
(n= 73) were displayed in an intensity graph, which indicated consis-
tencywithin the entire data set aswell as limited technical variation be-
tween scan dates (Fig. 1). The same data were subjected to principle
component analysis (PCA) using Partek Genomics Suite software.
Most of the experimental and technical replicate arrays for the different
experimental conditions clustered together in the PCA 3D scatter plots
(Fig. 2A–C), indicating high reproducibility of (i) the samples, despite
of the use of unmatched control donors and different E. coli concentra-
tions, and (ii) the hybridization protocol. PCA plots were generated for
the three series independently. Further, Pearson's correlation analyses
were performed using normalized and ﬁltered log2 intensities. The
Pearson correlation coefﬁcients (r) for each pair of arrays ranged fromN
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f t
ra
n
sc
rip
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Fig. 1. The intensity graph shows RMA normalized, unﬁltered log2 intensities for all 73 arrays. Th
same day are highlighted in the same color. See Table 1 for a detailed overview of the arrays a0.88 to 0.99 and reﬂected the overall consistency, also of the ﬁltered
data set (Fig. 3).
The PCA plots revealed donor-speciﬁc clustering of arrays for Ctrls
(Fig. 2A), which needed to be considered for downstream statistical
analyses. Arrays for C5D (Fig. 2B) and C5DR (Fig. 2C) could be found
in two separated clusters, where one of them contained the arrays of
the CD14-inhibited response (anti-CD14), combined inhibited response
(anti-CD14 + compstatin) and background activation (PBS), only. The
same clustering was observed for Ctrls, when only a limited number
of genes (n = 7786) was included according to an ANOVA, which re-
moved the noise from non-signiﬁcant differences (FDR q-value ≥0.1)
between experimental conditions (not shown). This observation is in
agreement with the high efﬁcacy of the combined inhibitory strategy
in our model and the increased importance of CD14 in C5D compared
to Ctrls [1].
Both, PCA and Pearson's correlation analysis revealed that the three
initial state control samples taken at time point zero (T0; GSM1338886,
GSM1338887, GSM1338888) as well as one single array of Ctrl2
(ctrl2_C5aR antagonist_D1; GSM1338836) correlated the least with any
other array. However, all correlation coefﬁcients were still high
(r ≥ 0.88), and none of the data sets were excluded. The low correlation
of the initial state controls is likely due to (i) the lack of intrinsic activationntensity
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Fig. 2.Principal component analysis (PCA) 3D scatter plotswere generated for all 73 arrays contained by the three series healthyblood donors (Ctrls) (A), C5-deﬁcient (C5D)blood (B), and
C5-reconstituted C5-deﬁcient (C5DR) blood (C). Colors indicate experimental conditions, while symbols indicate replicates from day 1 (D1, circle) andday 2 (D2, rectangle). The replicates
are either biological (two healthy blood donors, Ctrl and Ctrl2) (A) or technical (duplicate microarray analyses of D1 samples) (B and C). See Table 1 for a detailed overview of the arrays.
#Ctrl2 samples, *potential outlier array (GSM1338836; ctrl2_C5aR antagonist_D1), **T0 sample of Ctrl 2 (GSM1338886), ***T0 sample of Ctrl (GSM1338887), ****T0 sample of C5D
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at the end of the experiment, and (ii) the fact that those samples were
kept for 2 h on ice prior to lysis, compared to immediate lysis of the re-
maining samples. Notably, good correlation was observed between the
three T0 data sets (Fig. 3). No replicates were performed, here. The tran-
script intensities of the single outlier array (GSM1338836) correlated
rather well with those of the three replicate samples (GSM1338837,
GSM1338838, GSM1338839) as well as of the six samples from C5D
and C5DR containing the same inhibitor (GSM1338859, GSM1338860,
GSM1338861, GSM1338880, GSM1338881, GSM1338882) (Fig. 3).
The validity of the microarray data was proven by qPCR performed
on selected genes using the same RNA material [1].
2.5. Downstream statistical analyses
For interpretation of the results, which have been published else-
where [1], the normalized and ﬁltered log2 intensities of the 19,695
passed transcripts and for all 73 arrays were subjected to downstream
statistical analyses using linear models for microarray data (Limma
Bioconductor) [4,5]. To correct for multiple testing, FDR q-values were
computed from the p-values using the Benjamini–Hochberg method
for controlling the false discovery rate (FDR) [6]. Genes with FDR q-
values below 0.05 were considered to be signiﬁcantly differentially
expressed.Statistical signiﬁcance was determined for differential expression in
(i) uninhibited (presence of E. coli) vs. background activation (absence
of E. coli), and (ii) inhibited (presence of E. coli and inhibitors of C3
and CD14, alone or in combination, inhibitor of C5aR1, or inhibitor con-
trols) vs. uninhibited activation for each of the three series (Ctrls, C5D,
C5DR). Also, these data were compared across series (Ctrls vs. C5D,
Ctrls vs. C5DR, and C5D vs. C5DR).
For the two healthy donors (Ctrl and Ctrl2), fold change expression
estimates (log2FC) for each replicate were combined as follows. The es-
timates of day 1 (D1) and day 2 (D2)were pooled for each donor before
themean of both poolswas calculated. For C5D or C5DR, fold change es-
timates were calculated from the pooled data of the technical replicates
of D1 and from the data of D2, before the mean of both estimates was
calculated. The technical replicate, which substituted for the lack of a bi-
ological one for C5D and C5DR, contributed to higher correlation be-
tween data sets compared to data sets from healthy donors, and thus
to a higher statistical signiﬁcance.
Of the 19,695 transcripts included in the analysis, 2335 had an FDR
q-value below 0.05 for the uninhibited E. coli response vs. background
activation in healthy controls, and were designated E. coli-responsive
genes (ERGs). For all ﬁnal analyses only the data sets for ERGs were test-
ed for statistical signiﬁcance.
For detailed tests of combined inhibitory versus single inhibitory ef-
fects, analysis of variance (ANOVA) was applied [1].
Fig. 3. Pearson correlation coefﬁcients (r) were estimated for each pair of arrays using the RMA normalized, ﬁltered log2 intensities of the 19,695 passed transcripts and all 73 arrays. The
arrays are arranged according to the three series healthy donors (Ctrls), C5-deﬁcient (C5D) andC5-reconstituted C5-deﬁcient (C5DR). Arrays are indicatedwith their GEOdepository sam-
ple IDs. See Table 1 for a detailed overview of the arrays. The heat mapwas generated using the heatmap.2 function in library gplots (http://cran.r-project.org/package=gplots). A histo-
gramof r values is shown,with thedensity of arrayswith respective r values indicated as a blue line. *Potential outlier array (GSM1338836; ctrl2_C5aR antagonist_D1), **T0 sample of Ctrl 2
(GSM1338886), ***T0 sample of Ctrl (GSM1338887), ****T0 sample of C5D (GSM1338888).
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The replicate combination strategy for healthy controls was based
on the observation that the inﬂammatory response was more depen-
dent on the donor (male MBL defect versus female MBL sufﬁcient)
than on variations in E. coli concentrations used here. No signiﬁcant
E. coli concentration-dependent changes were found for healthy con-
trols (FDR q-value b0.05),when pooled fold change data for uninhibited
vs. background activation ofD1 (1× 106/mL)were compared to those ofD2 (5 × 106/mL). In contrast, a reasonable but low number of responses
were signiﬁcantly donor-dependent, when uninhibited (n = 94) or
combined C3/CD14 inhibited (n=96) E. coli responses were compared
between healthy donors (Fig. 4A). Background activation was more
donor-dependent, with roughly 42% (n= 992) of all ERGs being differ-
entially affected between the two healthy controls (Fig. 4A). However,
only 10% (n = 95 = 41 + 15 + 39) of these genes were also donor-
dependent in the presence of E. coli, either with or without combined
inhibition, which were the most important experimental conditions
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Fig. 4. Venn diagrams based on Limma-derived gene lists containing statistical signiﬁcant fold changes (FDR q-value b0.05) for the indicated comparisons for the 2335 E. coli-responsive
genes (ERGs). Numbers of ERGs with signiﬁcant changes are displayed within circles while numbers of the remaining ERGs with non-signiﬁcant changes are displayed in the lower right
corner. A, Log2 intensities of the 2335 ERGs contained by healthy control-speciﬁc (Ctrl or Ctrl2) CEL ﬁles for uninhibited E. coli response (E. coli) or initial state time point zero (T0) were
compared to those for background activation in absence of E. coli (PBS) for each healthy control alone. In the same way, combined C3 and CD14 inhibition was compared to uninhibited
response. Afterwards, signiﬁcant differences were established between the two control donors for the three comparisons entitled uninhibited, background activation, and C3/CD14 inhib. B,
ERG log2 intensities contained by all healthy control (Ctrls) CEL ﬁles for inhibitor controls (inhibitor ctrl) and combined C3 and CD14 inhibition (anti-CD14+Compstatin)were compared
to those for the uninhibited response (E. coli). Afterwards, signiﬁcant differences were established between the results of these analyses (C3/CD14 Inhib vs. Inhib ctrl). C and D, ERG log2
intensities contained by CEL ﬁles for the uninhibited response (E. coli) were compared to those for background activation (PBS) for healthy donors (Ctrls), C5-deﬁcient (C5D) and C5-
reconstituted C5-deﬁcient (C5DR), separately. Afterwards, signiﬁcant differences were established between Ctrls and C5DR (C; Ctrls vs. C5DR) and C5D and C5DR (D; C5D vs. C5DR).
See Table 1 for a detailed overview of the arrays and their CEL ﬁles.
182 C. Lau et al. / Genomics Data 5 (2015) 176–183tested in this study. In our study, these observed donor-dependent dif-
ferences could be due to various factors including age and sex. Also, we
cannot exclude that MBL deﬁciency affects the inﬂammatory response
on the transcriptional level, although we have not seen alterations in
functional read-outs [2].
Further,we controlled for non-speciﬁc effects induced by the admin-
istration of inhibitor molecules per se. Combined inhibition of C3 and
CD14 led to signiﬁcant differential expression of 1687 ERGs compared
to the uninhibited response (Fig. 4B). Administration of the inhibitor
control cocktail affected only 84 ERGs, most of which (n= 53) had sig-
niﬁcantly different effects than combined inhibition. Caremust be taken
when interpreting the results for the remaining 18 transcripts. Here,
combined inhibition and control inhibition had almost indistinguish-
able effects, which were, however, rather minor (below two-fold com-
pared to uninhibited) (not shown).C5-reconstitution of C5D had earlier been shown by Lappegård et al.
to fully restore C5-dependent functions like monocyte tissue factor and
CD11b expression, phagocytosis and oxidative burst [2]. Importantly,
C5-reconstitution of C5-deﬁcient blood (C5DR) was functionally sufﬁ-
cient also on the gene expression level. C5DR resembled healthy
donor samples (Ctrls) more than C5D when signiﬁcant differences in
gene expression betweenC5DRandCtrls or C5Dwere estimated. For ex-
ample, for the uninhibited response to E. coli, 60 and 336 ERGs
responded signiﬁcantly different in Ctrls compared to C5DR and C5D
compared to C5DR, respectively (Fig. 4C and D).
3. Discussion
The here described comprehensive set of microarray data allows for
(i) studying gene expression in the inﬂammatory response to Gram-
183C. Lau et al. / Genomics Data 5 (2015) 176–183negative bacteria induced in an ex vivo human whole blood model, (ii)
characterization of the role of innate immunity key components,
i.e., complement and CD14, and (iii) identiﬁcation of potential sepsis
markers. Applying statistical analyseswithmultiple testing, we detected
a reasonable large number of signiﬁcant differences with interpretable
fold changes. We found 2335 (12%) of all included 19,695 transcripts
to respond signiﬁcantly to treatment with E. coli in healthy donor
blood, with 362 respondingmore than two-fold compared to untreated.
Of the 2335 transcripts, 72% were affected by combined inhibition of C3
and CD14, whichwas themost efﬁcient inhibition strategy tested. Using
blood of a C5-deﬁcient individual, either C5-reconstituted (C5DR) or not
(C5D), shed light on the C5-dependency of the transcriptional response
and the role of CD14 in another innate immunity key component-
deﬁcient background. Importantly, C5 deﬁciency is very rare. At the
time point of the present study, the here involved C5-deﬁcient individ-
ual was the only one known in Norway.
Despite a limited number of donors, three to four replicate data sets
of each experimental condition were generated for three independent
series (healthy donor, C5D, and C5DR) in order to strengthen the down-
stream statistical analyses. We suggest our general observations to be
representative and indicative for subsequent studies. However, since
transcriptional responses can in fact be donor-dependent, the general
value for effects on single genes should be further tested by including
more healthy donors. Microarray analysis is a high throughput ap-
proach, allowing for the study ofmore than 20,000 transcripts in various
conditions, as long as high quality RNA can be retrieved. The here pre-
sented RNA proﬁle reﬂects the reprogramming of blood cells in re-
sponse to bacterial challenge. However, the response to such acute
insults occurs not only on the level of transcription. On the contrary,
the extension of the present study into the ﬁelds of more instantposttranscriptional and, most importantly, epigenetic regulations
would further contribute to the overall understanding of innate immu-
nity in systemic inﬂammation, either sterile or bacteria-induced.Acknowledgments
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